Efficiency (advantages) of ramipril in arterial hypertension and diabetes mellitus from the point of view of evidence-based medicine

AH and diabetes mellitus are comorbid diseases and are interconnected by general pathophysiological mechanisms of development, similar to cardiovascular complications. The presence of a close relationship between AH and diabetes mellitus is due to the importance of activation of the renin-angiotensin-aldosterone system, which underlies the remodeling of the cardiovascular sys­tem and the development of complications. According to modern clinical guidelines, ACE inhibitors are the drugs of choice in the treatment of AH in combination with diabetes mellitus. The use of ACE inhibitors in patients with AH and diabetes mellitus is accompanied by a reduction in the relative risk of cardiovascular outcomes and mortality. A scientific review of major clinical stud­ies with the results of efficacy of ACE inhibitor ramipril in patients with AH and diabetes mellitus is presented. Ramipril has a high affinity for ACE-1 and kinase II enzymes, pronounced clinical and organoprotective effects, proven to influence the prognosis. The HOPE study showed a 22% reduction in cardiovascular outcomes and mortality in high-risk patients treated with Ramipril (p < 0.001), and a 25% reduction in a subgroup of patients with diabetes mellitus. In a large retrospective cohort analysis, ramipril had a lower risk of mortality in patients with AH and diabetes mellitus compared to other ACE inhibitors (captopril, enalapril, fosinopril). In a number of studies (ATLANTIS, MICRO-HOPE, DIABHYCAR) in patients with diabetes mellitus and MAU, ramipril contributed to a significant slowdown of MAU progression and a significant regression of MAU, reducing the risk of diabetic nephropathy by 22%. This confirms the pronounced nephroprotective effect for primary and secondary nephropathy prevention. Several studies (AASK, HOPE, DREAM, ADaPT) using ramipril have shown a 17-36% reduction in the risk of the development of new cases of type 2 diabetes mellitus.

Thus, the evidence on the efficacy of ramipril has allowed to expand indications for its use not only for cardiovascular diseases (AH, chronic heart failure, MI), but also for diabetes mellitus and diabetic nephropathy, which significantly differs the drug from other ACE inhibitors.

1. Petrie J.R., Guzik TJ., Touyz R.M. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34(5):575-584. doi: 10.1016/j.cjca.2017.12.005.

2. Lastra G., Syed S., Kurukulasuriya L.R., Manrique C., Sowers J.R. Type 2 diabetes mellitus and hypertension: An update. Endocrinol Metab Clin North Am. 2014;43(1):103-122. doi: 10.1016/j.ecl.2013.09.005.

3. Chen G., McAlister F.A., Walker R.L., Hemmelgarn B.R., Campbell N.R. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57(5):891-897. doi: 10.1161/HYPERTENSIONAHA.110.162446.

4. Alderman M.H., Cohen H., Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension. 1999;33(5):1130-1134. doi: 10.1161/01.hyp.33.5.1130.

5. Safar M.E., Gnakamene J.B., Bahous S.A., Yannoutsos A., Thomas F. Longitudinal Study of Hypertensive Subjects With Type 2 Diabetes Mellitus: Overall and Cardiovascular Risk. Hypertension. 2017;69(6):1029-1035. doi: 10.1161/HYPERTENSIONAHA.116.08962.

6. Volpe M., Battistoni A., Savoia C., Tocci G. Understanding and treating hypertension in diabetic populations. Cardiovasc Diagn Ther. 2015;5(5):353-363. doi: 10.3978/j.issn.2223-3652.2015.06.02.

7. López-Sendón J., Swedberg K., McMurray J., Tamargo J., Maggioni A.P, et al.; Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J. 2004;25(16):1454-1470. doi: 10.1016/j.ehj.2004.06.003.

8. Regoli D., Gobeil FJ. Critical insights into the beneficial and protective actions of the kallikrein-kinin system. Vascul Pharmacol. 2015;64:1-10. doi: 10.1016/j.vph.2014.12.003.

9. Gavras I., Gavras H. Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Curr Opin Endocrinol Diabetes. 2002;9(4):323-328. Available at: https://journals.lww.com/co-endocrinology/Abstract/2002/08000/Metabolic_effects_of_angiotensin_converting_enzyme.5.aspx.

10. Cheng J., Zhang W., Zhang X., Han F., Li X., He X., Li Q., Chen J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773-785. doi: 10.1001/jamainternmed.2014.348.

11. Mancia G., Fagard R Narkiewicz K Redon J Zanchetti A Bohm Met al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-2219. doi: 10.1093/eurheartj/eht151.

12. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al.; ESC Scientific Document Group.2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.

13. Chazova I.E., Oshepkova E.V., Zhernakova Yu.V. et al. Clinical guidelines Diagnostics and treatment of arterial hypertension. Kardiologicheskiy vest-nik = Cardiology Bulletin. 2015;(1):3-30. (In Russ.) Available at: https//elibrary.ru/item.asp?id=23169125.

14. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Sistemnye gipertenzii = Systemic hypertension. 2019;16(1):6-31. (In Russ.) doi: 10.26442/2075082X.2019.1.190179.

15. Frampton J.E., Peters D.H. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995;49(3):440-466. doi: 10.2165/00003495-199549030-00008.

16. Ceconi C., Francolini G., Olivares A., Comini L., Bachetti T., Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007;577(1-3):1-6. doi: 10.1016/j.ejphar.2007.07.061.

17. Comini L., Bachetti T., Cargnoni A., Bastianon D., Gitti G.L., Ceconi C., Ferrari R. Therapeutic modulation of the nitric oxide: all ACE inhibitors are not equivalent. Pharm Res. 2007;56(1):42-48. doi: 10.1016/j.phrs.2007.03.004.

18. Gaisenok O.V., Martsevich S.Yu., BeLoLipetskayi V.G. Comprehensive Organoprotection in Patients With High Cardiovascular Risk: the PossibiLity of RamipriL From Positions of Evidence-Based Medicine. Kardiologiia. 2013;(9):90-4. (In Russ.) Available at: https//eLibrary.ru/item.asp?id=20809727.

19. Leonova M.V. Organoprotective effects of ramipriL in the treatment of arterial hypertension. Consilium Medicum. 2014;(01):7-12. (In Russ.) Available at: https//con-med.ru/magazines/consiLium_medicum/consiLi-um_medicum-01-2014/.

20. Heart Outcomes Prevention EvaLuation Study Investigators, Yosuf S., SLeight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipriL, on cardiovascuLar events in high-risk patients. The Heart Outcomes Prevention EvaLuation Study Investigators. N Engl J Med. 2000;342(3):145-153. doi: 10.1056/NEJM200001203420301.

21. Heart Outcomes Prevention EvaLuation (HOPE) Study Investigators. Effects of ramipriL on cardiovascuLar and microvascuLar outcomes in peopLe with diabetes meLLitus: resuLts of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention EvaLuation Study Investigators. Lancet. 2000;355(9200):253-259. https//Www.ncbi.nLm.nih.gov/pubmed/10675071.

22. Fisher M., SmaLL M., Kesson C. HOPE and MICRO-HOPE: review of the resuLts and impLications for peopLe with diabetes. Coronary Health Care. 2001;5(1):41-44. doi: 10.1054/chec.2001.0111.

23. Chang C.H., Lin J.W., Caffrey J.L., Wu L.C., Lai M.S. Different angiotensinconverting enzyme inhibitors and the associations with overaLL and cause-specific mortaLities in patients with hypertension. Am J Hypertens. 2015;28(6):823-830. doi: 10.1093/ajh/hpu237.

24. Trevisan R., Tiengo A., for the North-East ItaLy MicroaLbuminuria Study Group. Effect of Low-Dose RamipriL on MicroaLbuminuria in Normotensive or MiLd Hypertensive Non-InsuLin-Dependent Diabetic Patients. Am J Hypertens. 1995;8(9):876-883. doi: 10.1016/0895-7061(95)00162-i.

25. O’Hare P., BiLbous R., MitcheLL T., O’ CaLLaghan CJ., Viberti G.C.; Ace-Inhibitor TriaL to Lower ALbuminuria in Normotensive InsuLin-Dependent Subjects Study Group. Low-dose ramipriL reduces microaLbuminuria in type 1 diabetic patients without hypertension: resuLts of a randomized controLLed triaL. Diabetes Care. 2000;23(12):1823-1829. doi: 10.2337/diac-are.23.12.1823.

26. Gerstein H.C. Reduction of cardiovascuLar events and microvascuLar compLications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev. 2002;18(S3):S82-S85. doi: 10.1002/dmrr.285.

27. Marre M., Lievre M., ChateLLier G., Mann J.F., Passa P., Menard J.; DIABHYCAR Study Investigators. Effects of Low dose ramipriL on cardiovascuLar and renaL outcomes in patients with type 2 diabetes and raised excretion of urinary aLbumin: randomised, doubLe bLind, pLacebo controLLed triaL (the DIABHYCAR study). BMJ. 2004;328(7438):495. doi: 10.1136/bmj.37970.629537.0D.

28. Gress T.W., Nieto F.J., Shahar E., Wofford M.R., Brancati F.L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes meLLitus. N Eng J Med. 2000;342(13):905-912. doi: 10.1056/NEJM200003303421301.

29. ELLiott WJ., Meyer P.M. Incident diabetes in cLinicaL triaLs of antihypertensive drugs: a network meta-anaLysis. Lancet. 2007;369(9557):201-207. doi: 10.1016/S0140-6736(07)60108-1.

30. Li Z., Li Y., Liu Y., Xu W., Wang Q. Comparative risk of new-onset diabetes meLLitus for antihypertensive drugs: A network meta-anaLysis. J Clin Hypertens. 2017;19(12):1348-1356. doi: 10.1111/jch.13108.

31. Abuissa H., Jones P.G., Marso S.P., O’Keefe J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor bLockers for prevention of type 2 diabetes: a meta-anaLysis of randomized cLinicaL triaLs. J Am Coll Cardiol. 2005;46(5):821-826. doi: 10.1016/j.jacc.2005.05.051.

32. Andraws R., Brown D.L. Effect of inhibition of the renin-angiotensin system on deveLopment of type 2 diabetes meLLitus (meta-anaLysis of randomized triaLs). Am J Cardiol. 2007;99(7):1006-1012. doi: 10.1016/j.amj-card.2006.10.068.

33. AL-MaLLah M., Khawaja O., Sinno M., ALzohaiLi O., Samra A.B. Do angiotensin converting enzyme inhibitors or angiotensin receptor bLockers prevent diabetes meLLitus? A meta-anaLysis. Cardiology Journal. 2010;17(5):448-456. AvaiLabLe at: https://www.ncbi.nLm.nih.gov/pub-med/20865674.

34. Norris K., Bourgoigne J., Gassman J., Hebert L., MiddLeton J., PhiLLips R.A, et aL. CardiovascuLar outcomes in the African American Study of Kidney Disease and Hypertension (AASK) TriaL. Am J Kidney Dis. 2006;48(5):739-751. doi: 10.1053/j.ajkd.2006.08.004.

35. DREAM TriaL Investigators. Bosch J., Yusuf S., Gerstein H.C., Pogue J., Sheridan P., Dagenais G., Diaz R., Avezum A., Lanas F., ProbstfieLd J., Fodor G., HoLman R.R. Effect of ramipriL on the incidence of diabetes. N Engl J Med. 2006;355(15):1551-1562. doi: 10.1056/NEJMoa065061.

36. Zidek W., Schrader J., Luders S., Matthaei S., HassLacher C. et aL. RamipriL-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovascular Diabetology. 2012;11:1. doi: 10.1186/1475-2840-11-1.